Literature DB >> 11123292

Activated T lymphocytes regulate hyaluronan binding to monocyte CD44 via production of IL-2 and IFN-gamma.

M C Levesque1, B F Haynes.   

Abstract

Interactions of the cell surface proteoglycan CD44 with the extracellular matrix glycosaminoglycan hyaluronan (HA) are important during inflammatory immune responses. Our previous studies indicated that monocyte HA binding could be induced by TNF-alpha. Moreover, monocyte HA binding could be markedly up-regulated by culturing PBMC with anti-CD3 (TCR complex) mAbs. The present study was undertaken to identify soluble factors and/or cell surface molecules of activated T lymphocytes that might regulate HA binding to monocytes. Abs to IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-10, IL-15, GM-CSF, IFN-gamma, and TNF-alpha were tested for their effects on anti-CD3 mAb-, Con A-, and PMA/ionomycin-mediated monocyte HA binding in PBMC cultures. Anti-TNF-alpha, anti-IL-2, and anti-IFN-gamma Abs, when added together to PBMC cultures, completely blocked Con A- and partially blocked anti-CD3- and PMA/ionomycin-induced monocyte HA binding. Furthermore, when added together to PBMC cultures, IL-2 and TNF-alpha induced high levels of monocyte HA binding. Likewise, IFN-gamma augmented TNF-alpha-induced monocyte HA binding. To investigate the role of T cell-monocyte direct contact in induction of monocyte HA binding, we studied PMA/ionomycin-activated, paraformaldehyde-fixed CD4(+) T cells in these assays. Fixed, PMA/ionomycin-activated CD4(+) T lymphocytes induced monocyte HA binding, but direct T cell-monocyte contact was not required. Moreover, anti-IFN-gamma and anti-TNF-alpha Abs blocked fixed PMA/ionomycin-activated CD4(+) T cell-induced monocyte HA binding. Taken together, these studies indicate roles for soluble T lymphocyte-derived factor(s), such as IL-2 and IFN-gamma, and a role for monocyte-derived TNF-alpha in Con A-, TCR complex-, and PMA/ionomycin-induced HA binding to monocyte CD44.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123292     DOI: 10.4049/jimmunol.166.1.188

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective.

Authors:  Mia Krolikoski; James Monslow; Ellen Puré
Journal:  Matrix Biol       Date:  2018-05-21       Impact factor: 11.583

2.  Multifaceted regulation of T cells by CD44.

Authors:  Bas Jg Baaten; Cheng-Rui Li; Linda M Bradley
Journal:  Commun Integr Biol       Date:  2010-11-01

3.  Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice.

Authors:  S Farkas; M Hornung; C Sattler; M Anthuber; U Gunthert; H Herfarth; H J Schlitt; E K Geissler; B M Wittig
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

Review 4.  Hyaluronan and Its Receptors: Key Mediators of Immune Cell Entry and Trafficking in the Lymphatic System.

Authors:  Louise A Johnson; David G Jackson
Journal:  Cells       Date:  2021-08-12       Impact factor: 6.600

5.  Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance.

Authors:  M Athanassiou-Papaefthymiou; O Shkeir; D Kim; V Divi; M Matossian; J H Owen; M J Czerwinski; P Papagerakis; J McHugh; C R Bradford; T E Carey; G T Wolf; M E Prince; S Papagerakis
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Jul-Sep       Impact factor: 3.219

6.  CCR2 and CD44 promote inflammatory cell recruitment during fatty liver formation in a lithogenic diet fed mouse model.

Authors:  Charlotte E Egan; Erin K Daugherity; Arlin B Rogers; Delbert S Abi Abdallah; Eric Y Denkers; Kirk J Maurer
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

7.  Expression of Fas antigen and Fas ligand in bronchoalveolar lavage from silicosis patients.

Authors:  Agnès Hamzaoui; Jamel Ammar; Hédia Graïri; Kamel Hamzaoui
Journal:  Mediators Inflamm       Date:  2003-08       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.